Observational and review-level evidence also suggests that micronutrient insufficiencies may occur during prolonged GLP-1RA therapy [94, 95, 101]
By exploring the intricacies of GLP-1 medication for weight loss, we can uncover the timeline of results and the factors that influence each individuals unique experience
A 2024 KFF study found Medicaid coverage could benefit 40% of adults and 26% of children with obesity, forcing policymakers to weigh cost, equity and long-term health outcomes as demand grows and new uses emerge
Currently, dental complications are not recognized as part of ongoing Ozempic-related legal claims
Since GLP-1 medications mimic the action of a peptide produced in the GI tract, most reported mild side effects are associated with the digestive tract
Tirzepatide: Weight Loss: Studies show an average weight loss of 21% to 25% of body weight